A Study of Retatrutide (LY3437943) in Participants Who Have Obesity or Overweight and Chronic Low Back Pain

NCT07035093 · Recruiting

Last updated 2026-05-28

This clinical trial is testing the medication retatrutide in adults who have obesity or overweight and long-term lower back pain to see how it affects their pain levels.

Status Recruiting Currently enrolling participants.

Phase Phase 3 Confirms effectiveness in a large group before approval.

Type Interventional (clinical trial)

Design Randomized, double-blind treatment study

Participants 586 people Planned (estimated).

Who can join Ages 18+ · all sexes

Timeline Started 2025-05 · est. completion 2027-09

Where 40 sites · Argentina, Canada, Poland, United States

What this study is testing ClinicalTrials.gov NCT07035093 ↗

Description as written by the study sponsor.

The main purpose of this study is to evaluate the efficacy and safety of retatrutide in relieving chronic low back pain in participants who have obesity or overweight. Participation in the study will last about 80 weeks.

Treatments tested

Retatrutide also known as LY3437943 Drug

Administered SC
Placebo Drug

Administered SC

Main thing measured	Change from Baseline in Pain Intensity Per Numeric Rating Scale
Sponsor	Eli Lilly and Company
Conditions studied	Obesity, Overweight, Chronic Low Back Pain (CLBP)
GLP-1 drugs	retatrutide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT07035093 ↗